SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-083969
Filing Date
2022-03-24
Accepted
2022-03-24 17:00:31
Documents
13
Period of Report
2022-03-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d291544d8k.htm   iXBRL 8-K 25584
2 EX-99.1 d291544dex991.htm EX-99.1 59983
  Complete submission text file 0001193125-22-083969.txt   220719

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA labp-20220324.xsd EX-101.SCH 2870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE labp-20220324_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE labp-20220324_pre.xml EX-101.PRE 11717
7 EXTRACTED XBRL INSTANCE DOCUMENT d291544d8k_htm.xml XML 3466
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 22767248
SIC: 2834 Pharmaceutical Preparations